FDA Gets Social, But Not Too Social
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is trying multiple channels in social media to communicate drug safety information, but its two-way communication capacity is lower than many would like.
You may also be interested in...
Pharma Companies Starting To Build Dedicated Digital Marketing/Social Media Staffs
Despite an uncertain regulatory environment and no clear way to link digital marketing and social media activities to revenues, pharmaceutical companies are starting to spend more on promotional activities in the digital realm compared to traditional media (TV/radio/print advertising) and are building dedicated staffs to support these activities.
FDA’s Social Media Guidance: As Industry Waits, How Watchful Should It Be?
In the absence of clear policy from the agency, GSK keeps careful eyes on Facebook, but experts disagree on the extent to which drug companies are required to actively monitor social media sites.
FDA Tracking Tweets, Blog Posts To Gauge Reach Of Drug Safety Communications
FDA is in the early stages of developing a plan for how to get the most dissemination bang for its risk communication bucks.